Abstract
Gliosarcoma (GSM) is a rare biphasic neoplasms of the central nervous system composed of a glioblastoma multiforme (GBM) admixed with a sarcomatous component. In clinical practice GSM is generally managed similarly to GBM. However, there are conflicting reports regarding their clinical aggressiveness, cell line of origin and possible prognosis compared with those of GBM. The objective of this study was to compare clinic-pathological features in GSM patients with the GBM patients during the same study period. 518 patients with GBM were treated at our hospital between 2008 and 2013, among them 51 were GSM. In this series the GSMs represented 9.8 % of all GBMs and included 58.8 % male with a median age of 44.7 years. The locations, all supratentorial, included temporal in 41.2 %, frontal in 25.5 %, parietal in 19.6 %, and occipital in 13.7 %. All patients underwent tumor resection followed by post-operative radiation and adjuvant chemotherapy. The O6-methylguanine-DNA methyltransferase promoter methylation studies were significantly more frequent in the GBMs than GSMs (80.1 % vs. 44.7 %, P < 0.001). The median progression free survival and overall survival for the patients with GSM were 8.0 and 13.0 months, respectively, as compared with 9.0 and 14.0 months in the GBM group (log rank test P = 0.001 and 0.004, respectively). The Cox proportional hazards regression model indicated that the extent of tumor resection (HR = 1.518, P = 0.009) and pathological types (HR = 0.608, P = 0.002) were the significant prognostic factors in our own series. With regard to clinical features and outcomes, GSM and GBM cannot be distinguished clinically. GSM in China may be managed similarly to GBM, with maximal safe surgical resection followed by chemo-radiotherapy. Our study adds further evidence to support GSM as a unique clinical entity with a likely worse prognosis than GBM.
Similar content being viewed by others
References
Zhang BY, Chen H, Geng DY, Yin B, Li YX, Zhong P, Wu JS, Wang XQ (2011) Computed tomography and magnetic resonance features of gliosarcoma: a study of 54 cases. J Comput Assist Tomogr 35:667–673
Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol 61:57–64
Miller CR, Perry A (2007) Glioblastoma. Arch Pathol Lab Med 131:397–406
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 11:183–191
Biswas A, Kumar N, Kumar P, Vasishta RK, Gupta K, Sharma SC, Patel F, Mathuriya SN (2011) Primary gliosarcoma–clinical experience from a regional cancer centre in north India. Br J Neurosurg 25:723–729
Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O’Fallon JR, Farr GJ (1998) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 89:425–430
Han SJ, Yang I, Tihan T, Prados MD, Parsa AT (2010) Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 96:313–320
Damodaran O, van Heerden J, Nowak AK, Bynevelt M, McDonald K, Marsh J, Lee G (2014) Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. J Clin Neurosci 21:478–481
Karremann M, Rausche U, Fleischhack G, Nathrath M, Pietsch T, Kramm CM, Wolff JE (2010) Clinical and epidemiological characteristics of pediatric gliosarcomas. J Neurooncol 97:257–265
Okami N, Kawamata T, Kubo O, Yamane F, Kawamura H, Hori T (2002) Infantile gliosarcoma: a case and a review of the literature. Childs Nerv Syst 18:351–355
Perry JR, Ang LC, Bilbao JM, Muller PJ (1995) Clinicopathologic features of primary and postirradiation cerebral gliosarcoma. Cancer 75:2910–2918
Kumar P, Singh S, Kumar P, Krishnani N, Datta NR (2008) Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years. J Cancer Res Ther 4:164–168
Salvati M, Caroli E, Raco A, Giangaspero F, Delfini R, Ferrante L (2005) Gliosarcomas: analysis of 11 cases do two subtypes exist? J Neurooncol 74:59–63
Morantz RA, Feigin I, Ransohoff JR (1976) Clinical and pathological study of 24 cases of gliosarcoma. J Neurosurg 45:398–408
Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, Brem H (2010) Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 66:530–537
Scott AW, Tyler BM, Masi BC, Upadhyay UM, Patta YR, Grossman R, Basaldella L, Langer RS, Brem H, Cima MJ (2011) Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials 32:2532–2539
Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH (2012) Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 107:643–650
Han SJ, Yang I, Tihan T, Chang SM, Parsa AT (2010) Secondary gliosarcoma: a review of clinical features and pathological diagnosis. J Neurosurg 112:26–32
Han SJ, Yang I, Otero JJ, Ahn BJ, Tihan T, McDermott MW, Berger MS, Chang SM, Parsa AT (2010) Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. J Neurosurg 112:990–996
Pettorini BL, Park YS, Caldarelli M, Massimi L, Tamburrini G, Di Rocco C (2008) Radiation-induced brain tumours after central nervous system irradiation in childhood: a review. Childs Nerv Syst 24:793–805
Feigin I, Allen LB, Lipkin L, Gross SW (1958) The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation. Cancer 11:264–277
Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J (2007) Gliosarcoma arising in oligodendroglial tumors (“oligosarcoma”): a clinicopathologic study. Am J Surg Pathol 31:351–362
Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H (2000) Genetic profile of gliosarcomas. Am J Pathol 156:425–432
Schittenhelm J, Erdmann T, Maennlin S, Will BE, Beschorner R, Bornemann A, Meyermann R, Mittelbronn M (2007) Gliosarcoma with chondroid and osseous differentiation. Neuropathology 27:90–94
Shintaku M, Miyaji K, Adachi Y (1998) Gliosarcoma with angiosarcomatous features: a case report. Brain Tumor Pathol 15:101–105
Albrecht S, Connelly JH, Bruner JM (1993) Distribution of p53 protein expression in gliosarcomas: an immunohistochemical study. Acta Neuropathol 85:222–226
Behling E, Birbe R, Veznadaroglu E, Andrews DW, Flanders A, Kenyon LC (2004) Gliosarcoma arising from an anaplastic ependymoma: a case report of a rare entity. Hum Pathol 35:512–516
Karremann M, Rausche U, Fleischhack G, Nathrath M, Pietsch T, Kramm CM, Wolff JE (2010) Clinical and epidemiological characteristics of pediatric gliosarcomas. J Neurooncol 97:257–265
Witwer BP, Salamat MS, Resnick DK (2000) Gliosarcoma metastatic to the cervical spinal cord: case report and review of the literature. Surg Neurol 54:373–379
Pietschmann S, von Bueren AO, Kerber MJ, Baumert BG, Kortmann RD, Muller K (2015) An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/gliosarcoma patients with metastases outside of the central nervous system. Plos One 10:e0121592
Pietschmann S, von Bueren AO, Henke G, Kerber MJ, Kortmann RD, Muller K (2014) An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013. J Neurooncol 120:451–457
Acknowledgments
The author appreciates Dr. Lin Luo and Dr. Jun-Mei Wang for pathology diagnosis of GSM and GBM, the pathology department, Beijing Neurosurgical Institute, Capital Medical University.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of Interest
No potential conflicts of interest were disclosed.
Additional information
Guobin Zhang and Shengyue Huang contributed equally to the work.
Rights and permissions
About this article
Cite this article
Zhang, G., Huang, S., Zhang, J. et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. J Neurooncol 127, 355–362 (2016). https://doi.org/10.1007/s11060-015-2046-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-015-2046-0